Recently, Shanghai FTZ Fund has invested in the domestic RNA interference (RNAi) innovation enterprise Ribo Medical. As an innovative drug R&D enterprise dedicated to the development of RNA interference technology, Ribo is the main pioneer of small nucleic acid technology and small nucleic acid pharmaceutical in China. China's state-owned capital venture capital fund, Hillhead capital and etc. are also involved in the company's financing.
